Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients

被引：0
|
作者：
Ramchandren, Sindhu
Guptill, Jeff
Antozzi, Carlo
Bril, Vera
Gamez, Josep
Meuth, Sven
Nowak, Richard
Quan, Dianna
Mantecon, Maria Teresa Sevilla
Ling, Leona
Zhu, Yaowei
Karcher, Keith
Sun, Hong
机构：
来源：
NEUROLOGY | 2022年 / 99卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S35 / S37
页数：5
相关论文
共 32 条
  • [1] SERUM AUTOANTIBODY LOWERING BY THE ANTI-FCRN MONOCLONAL ANTIBODY, NIPOCALIMAB, CORRELATES WITH CLINICAL IMPROVEMENT IN GENERALIZED MYASTHENIA GRAVIS PATIENTS
    Guptill, Jeffrey
    Antozzi, Carlo
    Bril, Vera
    Gamez, Josep
    Meuth, Sven G.
    Nowak, Richard
    Quan, Dianna
    Sevilla, Teresa
    Ling, Leona
    Zhu, Yaowei
    Karcher, Keith
    Ramchandren, Sindhu
    Sun, Hong
    [J]. MUSCLE & NERVE, 2022, 65 : S4 - S4
  • [2] Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study
    Bril, Vera
    Benatar, Michael
    Brock, Melissa
    Greve, Bernhard
    Kiessling, Peter
    Woltering, Franz
    Van den Bergh, Peter
    [J]. NEUROLOGY, 2019, 92 (15)
  • [3] Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
    Evoli, A
    Tonali, PA
    Padua, L
    Lo Monaco, M
    Scuderi, F
    Batocchi, AP
    Marino, M
    Bartoccioni, E
    [J]. BRAIN, 2003, 126 : 2304 - 2311
  • [4] CLINICAL IMPROVEMENT OF MYASTHENIA-GRAVIS BY TREATMENT WITH A CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY
    AHLBERG, R
    YI, Q
    PIRSKANEN, R
    MATELL, G
    SWERUP, C
    RIEBER, P
    RIETHMULLER, G
    HOLM, G
    LEFVERT, AK
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 681 : 552 - 555
  • [5] Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
    Taylor, Peter C.
    Schett, Georg
    Huizinga, Tom W. J.
    Wang, Qingmin
    Ibrahim, Fowzia
    Zhou, Bei
    Liva, Sophia G.
    Shaik, Jafar Sadik B.
    Xiong, Yuan
    Leu, Jocelyn H.
    Panchakshari, Rohit A.
    Loza, Matthew J.
    Ma, Keying
    Dhatt, Harman
    Rojo Cella, Ricardo
    Karyekar, Chetan S.
    Cuff, Carolyn A.
    Gao, Sheng
    Fei, Kaiyin
    [J]. RMD OPEN, 2024, 10 (02):
  • [6] The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis
    Marcuse, Florit
    Brandts, Lloyd
    Moens, Daan
    Damoiseaux, Jan
    Hochstenbag, Monique
    Hoeijmakers, Janneke G. J.
    Maessen, Jos G.
    De Baets, Marc
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1187 - 1197
  • [7] THE ASSOCIATION BETWEEN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY LEVEL AND CLINICAL IMPROVEMENT IN MYASTHENIA GRAVIS
    Marcuse, Florit
    Brandts, Lloyd
    Moens, Daan
    Damoiseaux, Jan
    Hochstenbag, Monique
    Hoeijmakers, Janneke
    Maessen, Jos
    De Baets, Marc
    [J]. MUSCLE & NERVE, 2022, 65 : S3 - S4
  • [8] THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS
    Nowak, R.
    Benatar, M.
    Ciafaloni, E.
    Howard, J.
    Leite, M.
    Utsugisawa, K.
    Vissing, J.
    Wu, Y.
    Abuhatzira, L.
    Katz, E.
    Ratchford, J.
    [J]. MUSCLE & NERVE, 2020, 62 : S115 - S115
  • [9] TREATMENT OF MYASTHENIA-GRAVIS WITH ANTI-CD4 ANTIBODY - IMPROVEMENT CORRELATES TO DECREASED T-CELL AUTOREACTIVITY
    AHLBERG, R
    YI, Q
    PIRSKANEN, R
    MATELL, G
    SWERUP, C
    RIEBER, EP
    RIETHMULLER, G
    HOLM, G
    LEFVERT, AK
    [J]. NEUROLOGY, 1994, 44 (09) : 1732 - 1737
  • [10] Anti-lipoprotein receptor-related protein 4 antibody titer correlates with the clinical course of myasthenia gravis
    Mori, Takayuki
    Sato, Atsushi
    Oka, Akira
    Higuchi, Osamu
    Mizuguchi, Masashi
    [J]. PEDIATRICS INTERNATIONAL, 2022, 64 (01)
1234